Tissue Regeneration Therapeutics Grants Excusive License for Perivascular Umbilical Cord Stromal/Stem Cell Technology for Family Banking
Toronto, Canada, February 16th 2016: Tissue Regeneration Therapeutics (TRT)
announced today an exclusive licensing agreement in the United Kingdom, most of
Continental Europe, Ireland, Iceland, UAE, Kuwait, Qatar, Oman, Bahrain, Jordan, and
Lebanon. The licensee will now be able to offer families the ability to store and extract
stem cells from the tissue surrounding the vessels of the umbilical cord, a rich source
of mesenchymal stromal/stem cells (MSCs). The proprietary extraction method is
enabled through TRT’s human umbilical cord perivascular cell (HUCPVC) patented
technology. The licensee plans on a commercial launch in the third quarter of this
year.
TRT is a progressive biotechnology company with a focus on the commercial development
of our patented Human Umbilical Cord PeriVascular Cell (HUCPVC) platform technology
and its TXP family of cell therapy products. TRT has discovered the world’s richest source
of mesenchymal stromal/stem cells (MSCs) with potent regenerative, angiogenic, anti-
inflammatory, and immuno-regulatory properties. Unique advantages of the TRT HUCPVC
platform technology are founded on the highly enriched source of these important cells
compared to other tissue sources. Specifically, HUCPVCs represent high cell yields at
harvest from tissue normally discarded at birth; high frequencies of mesenchymal stromal
cells within the harvested population, their increased biological potential compared to cells
derived from adult tissues and their inexhaustible supply.
About TRT
TRT is a Canadian Controlled Private Corporation (CCPC) with a focus on the commercial
development of their patented Human Umbilical Cord PeriVascular Cell (HUCPVC)
platform technology and its TXP cell therapy products. TRT is the only company in the
world to have issued and allowed patents in the USA, Europe and Australasia, for extraction
of these unique cells from umbilical cord tissue. TRT provides license opportunities to
collaborating partner companies in the regenerative medicine, defense, and cord banking
sectors. Additional information is available at https://www.verypowerfulbiology.com